Pancreatic Cancer Research

ResearcherRush University Medical CenterActive in the last 2 years

Ross Allen Abrams

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5609-4136; OpenAlex author ID A5017008744. Sources: OpenAlex.

Their work

Papers
24 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
93
Papers, trials and grants by year

2011: 5 papers · 2012: 4 papers · 2013: 3 papers · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers

Papers 24

  1. Beyond Opioids in Pancreatic Cancer: Palliative Radiotherapy and Celiac Plexus Radiosurgery. First author DOI 10.1016/j.semradonc.2025.07.005↗
  2. Adjuvant Radiation for Resected Pancreatic Cancer: Historical Review and Current State. Co-author DOI 10.1016/j.semradonc.2025.07.009↗
  3. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  4. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2020.08.042↗
  5. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1634/theoncologist.2019-0562↗
  6. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pa… Co-author DOI 10.1038/bjc.2017.95↗
  7. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000370↗
  8. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy… Co-author DOI 10.1016/j.ijrobp.2015.10.062↗
  9. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial. Co-author DOI 10.1016/j.radonc.2016.07.002↗
  10. Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.08.026↗
  11. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP tr… Co-author DOI 10.1016/j.radonc.2015.08.026↗
  12. Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer. Last author DOI 10.1016/j.clon.2014.06.003↗
  13. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiati… Co-author DOI 10.1016/j.ijrobp.2012.11.020↗
  14. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Co-author DOI 10.1016/s1470-2045(13)70021-4↗
  15. Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience. First author DOI 10.1097/coc.0b013e31823a53ce↗
  16. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Last author DOI 10.1016/j.ijrobp.2011.11.050↗
  17. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pa… Co-author DOI 10.1016/j.ijrobp.2012.02.051↗
  18. Evolving concepts regarding the use of radiotherapy in the adjuvant management of periampullary pancreatic adenocarcinoma. Co-author DOI 10.1097/ppo.0b013e3182758c84↗
  19. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful? Co-author DOI 10.1586/egh.12.3↗
  20. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for panc… Co-author DOI 10.1016/j.ijrobp.2010.07.1993↗
  21. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACO… First author DOI 10.1093/annonc/mdq384↗
  22. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of sa… Co-author DOI 10.1097/sla.0b013e3181fd271c↗
  23. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 t… Co-author DOI 10.1245/s10434-010-1282-y↗
  24. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S… Co-author DOI 10.1245/s10434-011-1630-6↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marcin Miszczyk · 1 shared paper, 2025 · strength 0.42
  2. Yaacov Richard Lawrence · 1 shared paper, 2025 · strength 0.42
  3. Karyn A. Goodman · 3 shared papers, 2012–2025 · strength 0.38
  4. Joseph M. Herman · 3 shared papers, 2011–2025 · strength 0.36
  5. William F. Regine · 5 shared papers, 2011–2021 · strength 0.29
  6. John Parker Hoffman · 5 shared papers, 2011–2021 · strength 0.29
  7. Howard P. Safran · 5 shared papers, 2011–2021 · strength 0.29
  8. John Starner · 1 shared paper, 2025 · strength 0.28
  9. Leila T. Tchelebi · 1 shared paper, 2025 · strength 0.28
  10. Somnath Mukherjee · 5 shared papers, 2013–2017 · strength 0.24
  11. Chris N Hurt · 5 shared papers, 2013–2017 · strength 0.24
  12. Christopher H. Crane · 3 shared papers, 2016–2021 · strength 0.24
  13. Al B. Benson · 3 shared papers, 2011–2021 · strength 0.16
  14. Edgar Ben‐Josef · 3 shared papers, 2012–2020 · strength 0.14
  15. Tim Maughan · 3 shared papers, 2013–2017 · strength 0.14
  16. Thierry Conroy · 1 shared paper, 2022 · strength 0.11
  17. Riccardo Casadei · 1 shared paper, 2022 · strength 0.11
  18. Jean‐Luc Van Laethem · 1 shared paper, 2022 · strength 0.11
  19. Narikazu Boku · 1 shared paper, 2022 · strength 0.11
  20. Johanna W. Wilmink · 1 shared paper, 2022 · strength 0.11
  21. Paula Ghaneh · 1 shared paper, 2022 · strength 0.11
  22. Geertjan van Tienhoven · 1 shared paper, 2022 · strength 0.11
  23. Markus Wolfgang Büchler · 1 shared paper, 2022 · strength 0.11
  24. Esther N. Pijnappel · 1 shared paper, 2022 · strength 0.11
  25. Marianne Sinn · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.